|
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 |
|
Age (years) | 43 | 42 | 72 | 56 | 63 | 39 |
|
Gender | Male | Female | Male | Female | Male | Female |
|
Race | Caucasian | Caucasian | Caucasian | Black | Caucasian | Caucasian |
|
Time on dialysis at initiation of antiviral therapy (months) | 4 | 8 | 9 | 60 | 9 | 5 |
|
Previous kidney transplantation | Yes | Yes | No | Yes | No | Yes |
|
Previous antiviral treatment | Partial responder | Partial responder | Partial responder | Partial responder | Naïve | Relapser |
|
HCV genotype | 1 | 1a | 1 | 1b | 1b | 1b |
|
Initial HCV RNA concentration (log IU/mL) | 4.3 | 5.63 | 6.55 | 5.52 | 5.8 | 5.36 |
|
Liver fibrosis at the initiation of viral therapy | F2 | F2 | — | F2 | F1 | F1-F2 |
|
Rapid virological response | Yes | No | Yes | Yes | Yes | Yes |
|
Undetectable viremia at the end of therapy | Yes | No | No | No | Yes | Yes |
|
Sustained virological response | Yes | No, stopped therapy at week 28 | No, breakthrough between weeks 24 and 48 | No, breakthrough between weeks 24 and 48 | No, relapse at six months after ceasing therapy | No, relapse at one month after ceasing therapy |
|
Decrease in Peg-IFN dose | No | Yes | Yes | Yes | No | No |
|
Decrease in ribavirin dose | No | No | No | Yes | No | No |
|
Decrease in boceprevir dose | No | Yes | No | Yes | No | No |
|
Concomitant therapy | Amlodipine, bisoprolol, furosemide, calcium, and darbepoetin | Amlodipine, valsartan furosemide, calcium, omeprazole, and darbepoetin | Irbesartan, aspirin, atenolol, simvastatin, and calcium | Calcium, aspirin, omeprazole, and levothyroxine | Simvastatin, amlodipine, and valsartan | Calcium, sevelamer carbonate, alfacalcidol, urapidil, and darbepoetin |
|
Long-term outcome | Had received a kidney transplant at 12 months after the end of therapy and was still not viremic at 4 months after transplantation | Still viremic and on a waiting list | Deceased or on a waiting at list 3 months after antiviral therapy was stopped | Still viremic on a waiting list | Had received a kidney transplant at 1 month after HCV relapse from a HCV-positive donor and was still viremic at 6 months after kidney transplantation | Had received a kidney transplant at 8 months after HCV relapse and was still viremic at 5 months after kidney transplantation |
|